OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market
OneMedNet signed its 12th channel-partner agreement, this time with a leading global pharmaceutical intelligence and data solutions provider that will distribute OneMedNet's U.S.-sourced, de-identified clinical data to pharma customers worldwide. The unnamed partner will pair OneMedNet's multimodal, direct-from-source clinical data with its own analytics to serve pharma clients across drug development, regulatory submissions, market access, and medical AI. The deal extends OneMedNet's commercial reach into the pharmaceutical market, which third-party research sizes at roughly $2.7 billion in 2026, projected to reach $7.1 billion by 2033.
Key figures
- Studies
- 270 million
- Network sites
- more than 2,300
- Patient journeys
- over 90 million
- Rwd market 2026 usd
- US$2.7 billion
- Channel partnership count
- 12
- Rwd market 2033 projection usd
- US$7.1 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.